Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from a Phase 2b clinical trial. The company announced it will study these topline data in deciding next steps for PTI-125 as a potential treatment. Alzheimer’s disease is characterized by the formation of aggregates (clumps) of misfolded proteins in the brain. PTI-125 is an investigational small molecule…
May 19, 2020May 19, 2020